Sponsor

Teva Branded Pharmaceutical Products R&D, Inc.

Clinical research sponsor

How to interpret these research links

Connected source records

The exact organization name Teva Branded Pharmaceutical Products R&D, Inc. appears in 128 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials128
Recruiting shown0
Roles2
SourceClinicalTrials.gov
Advertisement

Clinical trials

60 shown
Pharmacokinetic Profile and Safety of Fluticasone Propionate and Albuterol Sulfate in Combination When Compared to Fluticasone Propionate Multidose Dry Powder Inhaler (Fp MDPI) in Children Aged 4 to 11 Years OldNCT06290102 · lead sponsor · 2024-05-16
COMPLETED
A Study to Test if TEV-53275 is Effective in Relieving AsthmaNCT04847674 · lead sponsor · 2021-05-04
TERMINATED
A 24-Week Treatment Study to Compare Standard of Care Versus the eMDPI DS in Participants 13 Years or Older With AsthmaNCT04677959 · lead sponsor · 2021-02-16
COMPLETED
A 12-Week Treatment Study to Evaluate the Effectiveness of Albuterol Multidose Dry Powder Inhaler With Integrated Electronic Module Digital System (eMDPI DS) in Participants13 Years or Older With AsthmaNCT03890666 · lead sponsor · 2020-10-26
COMPLETED
A Study to Test if TEV-48574 is Effective in Relieving AsthmaNCT04545385 · lead sponsor · 2020-10-07
TERMINATED
A Study to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive DisorderNCT04041284 · lead sponsor · 2019-09-13
COMPLETED
A Study to Test if TV-46000 is Safe for Maintenance Treatment of SchizophreniaNCT03893825 · lead sponsor · 2019-04-17
COMPLETED
Study to Evaluate TV-46000 as Maintenance Treatment in Adult and Adolescent Participants With SchizophreniaNCT03503318 · lead sponsor · 2018-04-27
COMPLETED
Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD)NCT03256695 · lead sponsor · 2017-09-28
COMPLETED
An Imaging Study Using PET/CT to Characterize the Effect of Intravenous Reslizumab on Airway InflammationNCT02937168 · lead sponsor · 2017-05-08
TERMINATED
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic AsthmaNCT03052725 · lead sponsor · 2017-03-10
TERMINATED
A Study to Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With AsthmaNCT02969408 · lead sponsor · 2017-02-13
COMPLETED
Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate/Salmeterol Multidose Dry Powder InhalerNCT02980133 · lead sponsor · 2016-12-28
COMPLETED
A Study in Adult Patients With Nonalcoholic Steatohepatitis Who Also Have Type 2 DiabetesNCT02769091 · lead sponsor · 2016-09-30
WITHDRAWN
A Double Blind Open Label Comparator Study to Compare Treatments in 4 to 11 Year Old Patients With AsthmaNCT02680561 · lead sponsor · 2016-04-01
COMPLETED
Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate in Adolescent and Adult Patients 12 Years of Age and Older With Persistent AsthmaNCT02513160 · lead sponsor · 2015-09-30
COMPLETED
An Efficacy and Safety Study of Reslizumab Subcutaneous in Patients With Oral Corticosteroid Dependent Asthma and Elevated Blood EosinophilsNCT02501629 · lead sponsor · 2015-09-29
COMPLETED
Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood EosinophilsNCT02452190 · lead sponsor · 2015-09-28
COMPLETED
Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis Treated With Copaxone®NCT02499900 · lead sponsor · 2015-08-10
COMPLETED
Study to Determine the Pharmacokinetics and Tolerability of Fluticasone Propionate MDPI and Fluticasone Propionate/Salmeterol MDPI Compared to High Strength FLOVENT® DISKUS® and ADVAIR® DISKUS® in Patients With Persistent Asthma 12 Years of Age and OlderNCT02437604 · lead sponsor · 2015-05-01
COMPLETED
An Efficacy and Safety Profile of Inhaled TV48108 in Healthy Volunteers and COPD PatientsNCT02315144 · lead sponsor · 2015-04-01
TERMINATED
Study in Healthy Volunteers and COPD Patients to Evaluate the Efficacy and Safety of Inhaled TV46017NCT02315131 · lead sponsor · 2015-03-01
TERMINATED
A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to PlaceboNCT02284568 · lead sponsor · 2015-01-12
COMPLETED
A Study of 3 Doses of Tiotropium Hydrofluoralkane (HFA) Breath Actuated Inhaler (BAI), in Patients With Chronic Obstructive Pulmonary DiseaseNCT02203474 · lead sponsor · 2014-08-01
WITHDRAWN
Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent AsthmaNCT02175771 · lead sponsor · 2014-07-01
COMPLETED
Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent AsthmaNCT02139644 · lead sponsor · 2014-06-01
COMPLETED
Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Adult Patients With Persistent AsthmaNCT02141854 · lead sponsor · 2014-06-01
COMPLETED
Study to Evaluate the Mastery of Inhaler Technique for Budesonide Formoterol (BF) SPIROMAX® as Compared to SYMBICORT® TURBOHALER® as Treatment for Adult Participants With AsthmaNCT02062463 · lead sponsor · 2014-05-28
COMPLETED
A Chronic-Dose Safety and Efficacy Study of Albuterol Multi-Dose Dry Powder Inhaler in Pediatric AsthmaticsNCT02126839 · lead sponsor · 2014-05-01
COMPLETED
A Study to Evaluate 2 Doses Of Oral Administration Of Laquinimod Compared to Interferon ß-1a Administered by Injection in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)NCT01975298 · lead sponsor · 2014-01-01
WITHDRAWN
A 12-week Safety and Efficacy Study of Beclomethasone Dipropionate (80 and 160 mcg/Day) Delivered Via Breath-Actuated Inhaler (BAI) in Patients >=12 Years Old With Persistent AsthmaNCT02040779 · lead sponsor · 2013-12-26
COMPLETED
A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants Ages 4-11 Years Old With Persistent AsthmaNCT02040766 · lead sponsor · 2013-12-01
COMPLETED
A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants >=12 Years Old With Persistent AsthmaNCT02031640 · lead sponsor · 2013-12-01
COMPLETED
Efficacy and Safety Evaluation of Budesonide/Formoterol SPIROMAX® Inhalation Powder Versus SYMBICORT® TURBOHALER®NCT01803555 · lead sponsor · 2013-07-04
COMPLETED
Efficacy and Safety Comparison of Albuterol Spiromax® and ProAir® Hydrofluoroalkane (HFA) in Pediatric PatientsNCT01899144 · lead sponsor · 2013-07-01
COMPLETED
A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of RasagilineNCT01879748 · lead sponsor · 2013-06-01
COMPLETED
Safety and Tolerability of Glatiramer AcetateNCT01874145 · lead sponsor · 2013-06-01
COMPLETED
Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)NCT01857323 · lead sponsor · 2013-05-01
COMPLETED
Pharmacokinetic and Pharmacodynamic Profiles of Albuterol Spiromax® and ProAir® Hydrofluoroalkane (HFA) in Pediatric Patients With AsthmaNCT01844401 · lead sponsor · 2013-04-01
COMPLETED
The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)NCT01707992 · lead sponsor · 2013-02-20
COMPLETED
To Compare the Pharmacokinetics of Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease (COPD)NCT01785433 · lead sponsor · 2013-01-01
COMPLETED
Dose Ranging Study of the Salmeterol Component of Fluticasone /Salmeterol Spiromax Compared to Fluticasone Spiromax and Advair Diskus in Asthma SubjectsNCT01772368 · lead sponsor · 2013-01-01
COMPLETED
Efficacy of Inhaled Albuterol Spiromax® in Subjects With Persistent Asthma With Steady State PharmacokineticsNCT01747629 · lead sponsor · 2012-12-01
COMPLETED
A 12-week Study to Compare the Efficacy and Safety of Albuterol Spiromax® Versus a Placebo in People 12 Years and Older With Persistent AsthmaNCT01424813 · lead sponsor · 2012-12-01
COMPLETED
Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's DiseaseNCT01723228 · lead sponsor · 2012-11-01
COMPLETED
Safety Study of Albuterol Spiromax® in Subjects With AsthmaNCT01698320 · lead sponsor · 2012-10-01
COMPLETED
A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma MedicationsNCT01576718 · lead sponsor · 2012-04-01
COMPLETED
An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)NCT01578785 · lead sponsor · 2012-03-01
TERMINATED
A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Assessing the Safety and TolerabilityNCT01404117 · lead sponsor · 2012-03-01
WITHDRAWN
Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe AsthmaNCT01508936 · lead sponsor · 2012-02-01
COMPLETED
A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler in Adolescents and Adults Who Have Asthma That is Not Controlled by Asthma Medications Not Containing SteroidsNCT01479621 · lead sponsor · 2012-01-01
COMPLETED
Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic AsthmaNCT01290887 · lead sponsor · 2011-06-01
TERMINATED
A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic AsthmaNCT01287039 · lead sponsor · 2011-04-01
COMPLETED
A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic AsthmaNCT01285323 · lead sponsor · 2011-03-01
COMPLETED
A Study to Evaluate the Integrated Dose Counter on an Albuterol Hydrofluoroalkane (HFA) Metered Dose Inhaler (MDI)NCT01302587 · lead sponsor · 2011-03-01
COMPLETED
A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic AsthmaNCT01270464 · lead sponsor · 2011-02-01
COMPLETED
Study to Evaluate the Long-Term Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) in Patients Who Require Opioid Treatment for an Extended Period of TimeNCT01223365 · lead sponsor · 2010-10-01
COMPLETED
A Twelve Month Long Term Safety Study to Evaluate the Safety of Albuterol in a Dry Powder Inhaler With Both Repeated and as Needed DosingNCT01218009 · lead sponsor · 2010-10-01
TERMINATED
Neugranin in Breast Cancer Participants Receiving Doxorubicin/DocetaxelNCT01126190 · lead sponsor · 2010-06-30
COMPLETED
A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to PlaceboNCT01067521 · lead sponsor · 2010-06-22
COMPLETED

Drugs studied in this sponsor's trials

25 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Teva Branded Pharmaceutical Products R&D, Inc. as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.
placebo34
reslizumab9
rasagiline mesylate8
albuterol7
glatiramer acetate5
rasagiline5
beclomethasone dipropionate4
fluticasone propionate4
placebo RxCUI 8375 · Lead sponsor in 31 linked trial(s) · 0 currently recruiting 34 trials reslizumab RxCUI 1746889 · Lead sponsor in 9 linked trial(s) · 0 currently recruiting 9 trials rasagiline mesylate RxCUI 577300 · Lead sponsor in 8 linked trial(s) · 0 currently recruiting 8 trials albuterol RxCUI 435 · Lead sponsor in 6 linked trial(s) · 0 currently recruiting 7 trials glatiramer acetate RxCUI 84375 · Lead sponsor in 5 linked trial(s) · 0 currently recruiting 5 trials rasagiline RxCUI 134748 · Lead sponsor in 3 linked trial(s) · 0 currently recruiting 5 trials beclomethasone dipropionate RxCUI 1348 · Lead sponsor in 3 linked trial(s) · 0 currently recruiting 4 trials fluticasone propionate RxCUI 50121 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 4 trials prednisone RxCUI 8640 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 2 trials Qvar RxCUI 226084 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials Advair RxCUI 301543 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial albuterol Dry Powder Inhaler RxCUI 1649559 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial albuterol sulfate RxCUI 142153 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial Azilect RxCUI 635985 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial Betaseron RxCUI 82828 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial dexamethasone RxCUI 3264 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial docetaxel RxCUI 72962 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial fentanyl RxCUI 4337 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial formoterol RxCUI 25255 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial fremanezumab RxCUI 2056691 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial methacholine chloride RxCUI 40165 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial methylprednisolone RxCUI 6902 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial pegfilgrastim RxCUI 338036 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial ProAir RxCUI 647295 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial

Sponsor roles

lead sponsor105
collaborator23
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.